Research Article
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study
Figure 2
Kaplan-Meier analysis of progression-free survival and overall survival with log-rank tests for first-line sorafenib-treated patients () according to the Memorial Sloan Kettering Cancer Center (MSKCC) (a) and Heng (b) risk groups. PFS, progression-free survival; OS, overall survival; CI, confidence interval.
(a) |
(b) |
(c) |
(d) |